<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Can J Gastroenterol Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">Can J Gastroenterol Hepatol</journal-id><journal-id journal-id-type="publisher-id">CJGH</journal-id><journal-title-group><journal-title>Canadian Journal of Gastroenterology &#x00026; Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2291-2789</issn><issn pub-type="epub">2291-2797</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28349044</article-id><article-id pub-id-type="pmc">5350398</article-id><article-id pub-id-type="doi">10.1155/2017/4385161</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line<italic> Helicobacter pylori</italic> Eradication: A Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0381-200X</contrib-id><name><surname>Maruyama</surname><given-names>Masafumi</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Naoki</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kubota</surname><given-names>Daisuke</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Miyajima</surname><given-names>Masayuki</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1481-1029</contrib-id><name><surname>Kimura</surname><given-names>Takefumi</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tokutake</surname><given-names>Koujiro</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Imai</surname><given-names>Ryujiro</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fujisawa</surname><given-names>Toru</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mori</surname><given-names>Hiromitsu</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Matsuda</surname><given-names>Yoshiaki</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wada</surname><given-names>Shuichi</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Horiuchi</surname><given-names>Akira</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kiyosawa</surname><given-names>Kendo</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Gastroenterology, Nagano Red Cross Hospital, Nagano, Japan</aff><aff id="I2"><sup>2</sup>Department of Metabolic Regulation, Shinshu University Graduate School of Medicine, Matsumoto, Japan</aff><aff id="I3"><sup>3</sup>Digestive Disease Center, Showa Inan General Hospital, Komagane, Japan</aff><aff id="I4"><sup>4</sup>Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan</aff><author-notes><corresp id="cor1">*Masafumi Maruyama: <email>m.maruyama@nagano-med.jrc.or.jp</email></corresp><fn fn-type="other"><p>Academic Editor: Michael Beyak</p></fn></author-notes><pub-date pub-type="ppub"><year>2017</year></pub-date><pub-date pub-type="epub"><day>28</day><month>2</month><year>2017</year></pub-date><volume>2017</volume><elocation-id>4385161</elocation-id><history><date date-type="received"><day>27</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>18</day><month>1</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Masafumi Maruyama et al.</copyright-statement><copyright-year>2017</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<italic>Background</italic>. A new agent, potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer advantages over conventional<italic> H. pylori</italic> eradication therapies. We aimed to compare the eradication rate between VPZ-based treatment and PPI-based one.<italic> Methods</italic>. This randomized controlled trial was designed to assign 141 patients with<italic> H. pylori-</italic>positive gastritis to VPZ group (VPZ 20 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days) or PPI group (rabeprazole 20 mg or lansoprazole 30 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days). Primary endpoints were eradication rates and adverse events.<italic> Results</italic>. Seventy of 72 patients in VPZ group and 63 of 69 patients in PPI group completed the treatment after 7 days. The eradication rate was significantly higher in VPZ group than PPI group by intention-to-treat analysis (95.8% versus 69.6%, <italic>P</italic> = 0.00003, 95% confidence interval [CI] 88.3-99.1% versus 57.3-80.1%) and per-protocol analysis (95.7% versus 71.4%, <italic>P</italic> = 0.0002, 95% CI 88.0-99.1% versus 58.7-82.1%). The incidence of adverse events was not different between the groups (26.3% in VPZ group versus 37.7% in PPI group, <italic>P</italic> = 0.15).<italic> Conclusion</italic>. VPZ-based regimen is more useful than that PPI-based regimen as a first-line<italic> H. pylori</italic> eradication therapy.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Helicobacter pylori (<italic>H. pylori</italic>) is a main cause of chronic gastritis and is related to gastric carcinogenesis [<xref rid="B1" ref-type="bibr">1</xref>]. A large-scale prospective randomized study clearly demonstrated that<italic> H. pylori</italic> eradication therapy deduced the relative risk of gastric cancer [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>]. Since<italic> H. pylori</italic> serves as an initiator and promotor during gastric carcinogenic process [<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>], it is widely accepted that complete eradication of<italic> H. pylori</italic> is beneficial for chronic gastritis patients.</p><p>The most widely prescribed regimen for a first-line<italic> H. pylori</italic> eradication has been a triple therapy with proton pump inhibitor (PPI), amoxicillin (AMX), and clarithromycin (CLR) [<xref rid="B7" ref-type="bibr">7</xref>&#x02013;<xref rid="B10" ref-type="bibr">10</xref>]. However, the eradication rate of PPI-based regimen has been declining over the years, mainly due to insufficient effects to antibiotics [<xref rid="B11" ref-type="bibr">11</xref>&#x02013;<xref rid="B14" ref-type="bibr">14</xref>]. To exert sufficient<italic> H. pylori</italic>-killing effect of AMX and CLR, maintenance of intragastric pH around 6 to 7 is mandatory [<xref rid="B15" ref-type="bibr">15</xref>]. Therefore, development of potent gastric acid secretion-lowering agents is desired to improve the eradication rate.</p><p>Vonoprazan (VPZ), a first-in-class potassium-competitive blocker, can inhibit the H<sup>+</sup>, K<sup>+</sup>-ATPase-mediated gastric acid secretion in a reversible and potassium-competitive manner, possessing approximately 350 times more potent inhibitory effects than lansoprazole (LPZ), a typical PPI, in in vitro experiments [<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>]. VPZ is very stable in gastric juice, works immediately, and the effect lasts for a long time. Additionally, it undergoes substantial metabolic elimination independently of cytochrome P450 (CYP) 2C19 polymorphism [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>], which is distinct from PPI. This new agent is expected to offer clinical advantages over conventional PPI-based eradication therapies.</p><p>Recently, Murakami et al. reported the results of phase III noninferior trial that VPZ/AMX/CLR combination therapy is effective as a first- and second-line eradication for<italic> H. pylori</italic>-positive patients with a history of gastric or duodenal ulcer [<xref rid="B21" ref-type="bibr">21</xref>]. However, there is no prospective study verifying the superiority of VPZ-based regimen for a first-line<italic> H. pylori</italic> eradication. Therefore, we designed this randomized trial in order to compare the efficacy and safety between VPZ-based therapy and conventional PPI-based one.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Ethics</title><p>This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved on the Institutional Review Board of Nagano Red Cross Hospital and was registered in University Hospital Medical Information Network (registration number: ID21148) [<ext-link ext-link-type="uri" xlink:href="http://www.umin.ac.jp/">http://www.umin.ac.jp/</ext-link>].</p></sec><sec id="sec2.2"><title>2.2. Study Design</title><p>A phase IV randomized, single-blind, single-center, parallel-group comparative study was designed to assess the superiority of VPZ/AMX/CLR triple therapy to PPI/AMX/CLR therapy as a first-line<italic> H. pylori</italic> eradication. The enrollment criteria of the participants are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. From April 2015 to February 2016, 3680 persons received health checkup in Nagano Red Cross Hospital. Among them, 2778 persons wished to undergo esophagogastroduodenoscopy as a survey of upper gastrointestinal tract and 1482 were endoscopically diagnosed as having chronic active gastritis. All chronic gastritis patients who visited our hospital for the treatment received <sup>13</sup>C-urea breath test (UBT) using UBIT tablets (100&#x02009;mg, Otsuka pharmaceutical, Tokyo, Japan) and &#x00394;<sup>13</sup>C of more than 2.5&#x02030; was diagnosed as having<italic> H. pylori</italic> infection. We excluded 1341 subjects because of one of the following reasons: refusal of further examination, eradication therapy, or participation in this study, visit/consultation to other hospitals, 80 years old or older, poor status, requiring immediate treatment, posteradication, or negative results for UBT. According to the report from Murakami et al. [<xref rid="B21" ref-type="bibr">21</xref>], we hypothesized that the eradication rate of VPZ/AMX/CLR combination therapy would be around 90%. Based on our experience and other reports [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>], a first eradication rate in PPI-based protocol was approximately 70%. In order to demonstrate a superiority of VPZ-based regimen for a first-line<italic> H. pylori</italic> eradication, we calculated a sample size for comparing 90% in VPZ-based regimen versus 70% in PPI-based one with a two-sided <italic>&#x003b1;</italic> of 0.05 and a power of 80% and required at least 62 participants in each arm. Consequently, 141 UBT-positive chronic gastritis patients were diagnosed as having<italic> H. pylori</italic> infection, approved to participate in this randomized control trial, and received eradication therapy. Randomization was performed according to the personal medical record number, that is, odd number to PPI group and even one to VPZ group.</p></sec><sec id="sec2.3"><title>2.3. Eradication Regimen</title><p>The patients in VPZ group received VPZ 20&#x02009;mg, AMX 750&#x02009;mg, and CLR 200&#x02009;mg or 400&#x02009;mg twice daily for 7 days. The patients in PPI group received rabeprazole (RPZ) 20&#x02009;mg, AMX 750&#x02009;mg, and CLR 200&#x02009;mg or 400&#x02009;mg twice daily for 7 days or LPZ 30&#x02009;mg, AMX 750&#x02009;mg, and CLR 400&#x02009;mg twice daily for 7 day. Selection of RPZ or LPZ and CLR 200&#x02009;mg or 400&#x02009;mg was decided by each doctor.</p></sec><sec id="sec2.4"><title>2.4. Study Outcomes</title><p>The primary outcomes were<italic> H. pylori</italic> eradication rate and adverse event. Eradication success was evaluated using <sup>13</sup>C-UBT at 8 weeks after completing the treatment and &#x00394;<sup>13</sup>C of less than 2.5&#x02030; was judged as successful eradication. The eradication rate was assessed by intention-to-treat (ITT) and per-protocol (PP) analysis. Adverse events were also evaluated at 8 weeks after finishing the treatment using a questionnaire.</p></sec><sec id="sec2.5"><title>2.5. Statistical Analyses</title><p>Statistical analyses were performed using the excel toukei (SSRI Co, Tokyo, Japan). Categorical and continuous variables were compared with <italic>&#x003c7;</italic><sup>2</sup> test or Fisher's exact test (when the group contained 5 or less than 5 subjects) and Mann&#x02013;Whitney <italic>U</italic> test, respectively. A<italic> P</italic> value of less than 0.05 was considered as statistically significant.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Baseline Characteristics of the Participants</title><p>Among 141 participants, 72 and 69 subjects received VPZ-based and PPI-based treatment, respectively (<xref ref-type="fig" rid="fig1">Figure 1</xref>). There were no significant differences in clinical parameters of the patients, such as age, body mass index, frequency of male, smoker, drinker, comorbidities, serum levels of liver enzymes and creatinine, and glycohemoglobin values between the groups (<xref ref-type="table" rid="tab1">Table 1</xref>). Two patients in the VPZ and 6 patients in the PPI group missed doses of the medications; therefore the completion rate was 97% (70/72) and 91% (63/69) in the VPZ and PPI group, respectively. No drop-off was observed due to serious adverse effects, treatment side effects, and withdrawal from study participation.</p></sec><sec id="sec3.2"><title>3.2. Eradication Rate</title><p>The eradication rate was greater in VPZ-based therapy compared with PPI-based one by ITT analysis (95.8% versus 69.6%, <italic>P</italic> = 0.00003; 95% confidence interval [CI] 88.3&#x02013;99.1 versus 57.3&#x02013;80.1%) (<xref ref-type="fig" rid="fig2">Figure 2(a)</xref>), as well as PP analysis (95.7% versus 71.4%, <italic>P</italic> = 0.0002; 95% CI 88.0&#x02013;99.1 versus 58.7&#x02013;82.1%) (<xref ref-type="fig" rid="fig2">Figure 2(b)</xref>). When the eradication rate was compared between VPZ and RPZ, a widely prescribed PPI in Japan, it was significantly higher in the former regimen in both analyses (Figures <xref ref-type="fig" rid="fig3">3(a)</xref> and <xref ref-type="fig" rid="fig3">3(b)</xref>). Additionally, there were no significant differences in the eradication rate between 200&#x02009;mg and 400&#x02009;mg of CLR in VPZ group (94.7% versus 100%, <italic>P</italic> = 1.00) and RPZ group (75.6% versus 42.9%, <italic>P</italic> = 0.05), respectively, by ITT analysis, as well as PP analysis (94.5% versus 100%, <italic>P</italic> = 1.00 and 75.6% versus 46.2%, <italic>P</italic> = 0.10).</p></sec><sec id="sec3.3"><title>3.3. Adverse Events</title><p>Incidence of adverse events was not different between the groups (26.3% in VPZ group versus 37.7% in PPI group, <italic>P</italic> = 0.15). The common adverse events was loose stool, diarrhea, dysgeusia, and skin eruption (<xref ref-type="table" rid="tab2">Table 2</xref>). Suppressed gastric acid secretion can raise circulating gastrin levels. However, serum gastrin concentrations at 8 weeks after the completion of treatment were similar between VPZ group (median 102&#x02009;pg/mL, range 22&#x02013;970) and PPI group (181&#x02009;pg/mL, 23&#x02013;1200) (<italic>P</italic> = 0.12).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>The current randomized controlled trial was designed to assess the efficacy and safety of VPZ-based triple therapy and verified its superiority to conventional PPI-based therapy as a first-line<italic> H. pylori</italic> eradication. The results in this prospective study were in agreement with the results of the recent phase III noninferior trial for<italic> H. pylori</italic>-positive patients with a history of gastric or duodenal ulcer. Overall, a new VPZ/AMX/CLR treatment can be recommended for na&#x000ef;ve<italic> H. pylori</italic>-infected patients.</p><p>VPZ, a first-in-class potassium-competitive blocker, is structurally stable, activated even in gastric acid, and absorbed rapidly and reaches maximum plasma concentration at 1.5&#x02013;2.0 hours after single oral administration [<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B20" ref-type="bibr">20</xref>]. It is highly concentrated in the acidic canaliculi of the gastric parietal cells, exerting an acid-suppressive effect for longer than 24 hours [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>]. Accordingly, VPZ raises the gastric pH levels above 4.0 as early as 4 hours after single administration and maintains them for more than 24 hours [<xref rid="B18" ref-type="bibr">18</xref>]. Indeed, the acid-inhibiting potency is approximately 350 times greater than LPZ [<xref rid="B18" ref-type="bibr">18</xref>]. Since the most suitable gastric pH for antibiotics is around 6, the strong, immediate, and persistent effect of VPZ likely contributes to higher eradication rate compared with PPI.</p><p>Another possible advantage of VPZ is that it is not metabolized through CYP2C19. PPI is mainly metabolized by CYP2C19 and its gene polymorphism can affect PPI elimination from the body. Furuta et al. reported that the patients carrying CYP2C19 genotype associated with rapid extensive PPI metabolizers had lower eradication success rate after PPI/AMX/CLR therapy compared with poor metabolizers [<xref rid="B24" ref-type="bibr">24</xref>]. The frequency of CYP2C19 genotype of rapid extensive metabolizers is reported to be approximately 30% of Asians and 80% of Caucasian, respectively [<xref rid="B24" ref-type="bibr">24</xref>]. Therefore, VPZ-based therapy is also useful for PPI rapid extensive metabolizers.</p><p>CLR-containing triple therapy for 7 to 14 days is a standard first-line regimen in Asia [<xref rid="B14" ref-type="bibr">14</xref>], but the eradication rate has fallen below 80% in many Asian countries [<xref rid="B14" ref-type="bibr">14</xref>], which is consistent with the results of the present study that the eradication rate of PPI/AMX/CLR therapy was as low as 70%. Reduced eradication rate of traditional PPI/AMX/CLR is presumably due to insufficient bacteria-killing effect of CLR. Indeed, CLR-insensitive rate was higher than 15% in several Asian countries, such as Japan, China, and India [<xref rid="B14" ref-type="bibr">14</xref>]. Greater eradication rate in VPZ/AMX/CLR compared with PPI/AMX/CLR suggests that VPZ enhances the antibacterial effect of CLR.</p><p>The limitation of this prospective trial was small number of the patients in a single medical center. Additionally, there were no significant differences in the incidence of adverse events between the both groups in the present study, but Suzuki et al. reported the incidence of skin rash was significantly higher in VPZ therapy [<xref rid="B25" ref-type="bibr">25</xref>]. Further large-scale multicenter studies are needed to confirm the efficacy and safety of VPZ-based treatment.</p></sec><sec id="sec5"><title>5. Conclusion</title><p>In conclusion, VPZ-based regimen is safe and more efficacious than PPI-based regimen as a first-line<italic> H. pylori</italic> eradication therapy. VPZ may be a key agent to improve<italic> H. pylori</italic> eradication rate and prevent gastric cancer.</p></sec></body><back><sec sec-type="COI-statement"><title>Competing Interests</title><p>The authors have no conflict of interests to disclose.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="book"><collab>IARC</collab><source><italic>Schistosomes, Liver Flukes and Helicobacter pylori</italic></source><year>1994</year><volume>61</volume><publisher-loc>Lyon, France</publisher-loc><publisher-name>IARC Working Group on the Evaluation of Carcinogenic Risks to Humans</publisher-name><series>IARC Monographs on the Evaluation of Carcinogenic Risks to Humans</series></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Martel</surname><given-names>C.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Franceschi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Global burden of cancers attributable to infections in 2008: a review and synthetic analysis</article-title><source><italic>The Lancet Oncology</italic></source><year>2012</year><volume>13</volume><issue>6</issue><fpage>607</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/s1470-2045(12)70137-7</pub-id><pub-id pub-id-type="other">2-s2.0-84861648384</pub-id><pub-id pub-id-type="pmid">22575588</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.-C.</given-names></name><name><surname>Chiang</surname><given-names>T.-H.</given-names></name><name><surname>Chou</surname><given-names>C.-K.</given-names></name><etal/></person-group><article-title>Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis</article-title><source><italic>Gastroenterology</italic></source><year>2016</year><volume>150</volume><issue>5</issue><fpage>1113e5</fpage><lpage>1124.e5</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.01.028</pub-id><pub-id pub-id-type="other">2-s2.0-84964370106</pub-id><pub-id pub-id-type="pmid">26836587</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsugawa</surname><given-names>H.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Saya</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Reactive oxygen species-induced autophagic degradation of helicobacter pylori CagA is specifically suppressed in cancer stem-like cells</article-title><source><italic>Cell Host and Microbe</italic></source><year>2012</year><volume>12</volume><issue>6</issue><fpage>764</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2012.10.014</pub-id><pub-id pub-id-type="other">2-s2.0-84870999066</pub-id><pub-id pub-id-type="pmid">23245321</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valenzuela</surname><given-names>M. A.</given-names></name><name><surname>Canales</surname><given-names>J.</given-names></name><name><surname>Corval&#x000e1;n</surname><given-names>A. H.</given-names></name><name><surname>Quest</surname><given-names>A. F. G.</given-names></name></person-group><article-title>Helicobacter <italic>pylori</italic>-induced inflammation and epigenetic changes during gastric carcinogenesis</article-title><source><italic>World Journal of Gastroenterology</italic></source><year>2015</year><volume>21</volume><issue>45</issue><fpage>12742</fpage><lpage>12756</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i45.12742</pub-id><pub-id pub-id-type="other">2-s2.0-84948972903</pub-id><pub-id pub-id-type="pmid">26668499</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatematsu</surname><given-names>M.</given-names></name><name><surname>Tsukamoto</surname><given-names>T.</given-names></name><name><surname>Toyoda</surname><given-names>T.</given-names></name></person-group><article-title>Effects of eradication of Helicobacter pylori on gastric carcinogenesis in experimental models</article-title><source><italic>Journal of Gastroenterology</italic></source><year>2007</year><volume>42</volume><issue>17</issue><fpage>7</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00535-006-1927-6</pub-id><pub-id pub-id-type="other">2-s2.0-33846448157</pub-id><pub-id pub-id-type="pmid">17238018</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gisbert</surname><given-names>J. P.</given-names></name><name><surname>Calvet</surname><given-names>X.</given-names></name></person-group><article-title>Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough</article-title><source><italic>Alimentary Pharmacology and Therapeutics</italic></source><year>2011</year><volume>34</volume><issue>11-12</issue><fpage>1255</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2011.04887.x</pub-id><pub-id pub-id-type="other">2-s2.0-81355146380</pub-id><pub-id pub-id-type="pmid">22017749</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P.</given-names></name><name><surname>Megraud</surname><given-names>F.</given-names></name><name><surname>O'Morain</surname><given-names>C. A.</given-names></name><etal/></person-group><article-title>Management of <italic>Helicobacter pylori</italic> infection&#x02014;the maastricht IV/florence consensus report</article-title><source><italic>Gut</italic></source><year>2012</year><volume>61</volume><fpage>646</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">22491499</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chey</surname><given-names>W. D.</given-names></name><name><surname>Wong</surname><given-names>B. C. Y.</given-names></name></person-group><article-title>American College of Gastroenterology guideline on the management of Helicobacter pylori infection</article-title><source><italic>American Journal of Gastroenterology</italic></source><year>2007</year><volume>102</volume><issue>8</issue><fpage>1808</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2007.01393.x</pub-id><pub-id pub-id-type="other">2-s2.0-34547619783</pub-id><pub-id pub-id-type="pmid">17608775</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asaka</surname><given-names>M.</given-names></name><name><surname>Kato</surname><given-names>M.</given-names></name><name><surname>Takahashi</surname><given-names>S.-I.</given-names></name><etal/></person-group><article-title>Guidelines for the management of <italic>Helicobacter pylori</italic> infection in Japan: 2009 revised edition</article-title><source><italic>Helicobacter</italic></source><year>2010</year><volume>15</volume><issue>1</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2009.00738.x</pub-id><pub-id pub-id-type="other">2-s2.0-74349106695</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>D. Y.</given-names></name><name><surname>Shiotani</surname><given-names>A.</given-names></name></person-group><article-title>New concepts of resistance in the treatment of Helicobacter pylori infections</article-title><source><italic>Nature Clinical Practice Gastroenterology and Hepatology</italic></source><year>2008</year><volume>5</volume><issue>6</issue><fpage>321</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1038/ncpgasthep1138</pub-id><pub-id pub-id-type="other">2-s2.0-44949243126</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liou</surname><given-names>J. M.</given-names></name><name><surname>Chen</surname><given-names>C.-C.</given-names></name><name><surname>Chang</surname><given-names>C.-Y.</given-names></name><etal/></person-group><article-title>Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of <italic>Helicobacter pylori</italic> in the community and hospital populations: a randomised trial</article-title><source><italic>Gut</italic></source><year>2015</year><volume>65</volume><issue>11</issue><fpage>1784</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2015-310142</pub-id><pub-id pub-id-type="other">2-s2.0-84940930258</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liou</surname><given-names>J.-M.</given-names></name><name><surname>Chang</surname><given-names>C.-Y.</given-names></name><name><surname>Chen</surname><given-names>M.-J.</given-names></name><etal/></person-group><article-title>The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors&#x02014;a nationwide study</article-title><source><italic>PLoS ONE</italic></source><year>2015</year><volume>10</volume><issue>5</issue><pub-id pub-id-type="publisher-id">e0124199</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0124199</pub-id><pub-id pub-id-type="other">2-s2.0-84929096058</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liou</surname><given-names>J. M.</given-names></name><name><surname>Wu</surname><given-names>M. S.</given-names></name><name><surname>Lin</surname><given-names>J. T.</given-names></name></person-group><article-title>Treatment of <italic>Helicobacter pylori</italic> infection&#x02014;where are we now?</article-title><source><italic>Journal of Gastroenterology and Hepatology</italic></source><year>2016</year><volume>31</volume><fpage>1918</fpage><lpage>1926</lpage><pub-id pub-id-type="pmid">27088632</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachs</surname><given-names>G.</given-names></name><name><surname>Scott</surname><given-names>D. R.</given-names></name><name><surname>Wen</surname><given-names>Y.</given-names></name></person-group><article-title>Gastric infection by <italic>Helicobacter pylori</italic></article-title><source><italic>Current Gastroenterology Reports</italic></source><year>2011</year><volume>13</volume><issue>6</issue><fpage>540</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1007/s11894-011-0226-4</pub-id><pub-id pub-id-type="other">2-s2.0-81255161707</pub-id><pub-id pub-id-type="pmid">21993716</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>Y.</given-names></name><name><surname>Imanishi</surname><given-names>A.</given-names></name><name><surname>Matsukawa</surname><given-names>J.</given-names></name><etal/></person-group><article-title>1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl] -N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases</article-title><source><italic>Journal of Pharmacology and Experimental Therapeutics</italic></source><year>2010</year><volume>335</volume><issue>1</issue><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1124/jpet.110.170274</pub-id><pub-id pub-id-type="other">2-s2.0-77957228369</pub-id><pub-id pub-id-type="pmid">20624992</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>Y.</given-names></name><name><surname>Mori</surname><given-names>Y.</given-names></name><name><surname>Okamoto</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects&#x02014;a randomised open-label cross-over study</article-title><source><italic>Alimentary Pharmacology and Therapeutics</italic></source><year>2015</year><volume>42</volume><issue>6</issue><fpage>719</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1111/apt.13325</pub-id><pub-id pub-id-type="other">2-s2.0-84939573904</pub-id><pub-id pub-id-type="pmid">26193978</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Echizen</surname><given-names>H.</given-names></name></person-group><article-title>The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations</article-title><source><italic>Clinical Pharmacokinetics</italic></source><year>2016</year><volume>55</volume><issue>4</issue><fpage>409</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1007/s40262-015-0326-7</pub-id><pub-id pub-id-type="other">2-s2.0-84961156522</pub-id><pub-id pub-id-type="pmid">26369775</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>Y.</given-names></name><name><surname>Nishimura</surname><given-names>A.</given-names></name><name><surname>Kennedy</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects</article-title><source><italic>Clinical and Translational Gastroenterology</italic></source><year>2015</year><volume>6, article e94</volume></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>H.</given-names></name><name><surname>Sakurai</surname><given-names>Y.</given-names></name><name><surname>Nishimura</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects</article-title><source><italic>Alimentary Pharmacology and Therapeutics</italic></source><year>2015</year><volume>41</volume><issue>7</issue><fpage>636</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1111/apt.13121</pub-id><pub-id pub-id-type="other">2-s2.0-84964207179</pub-id><pub-id pub-id-type="pmid">25707624</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>K.</given-names></name><name><surname>Sakurai</surname><given-names>Y.</given-names></name><name><surname>Shiino</surname><given-names>M.</given-names></name><name><surname>Funao</surname><given-names>N.</given-names></name><name><surname>Nishimura</surname><given-names>A.</given-names></name><name><surname>Asaka</surname><given-names>M.</given-names></name></person-group><article-title>Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for <italic>Helicobacter pylori</italic>eradication: a phase III, randomised, double-blind study</article-title><source><italic>Gut</italic></source><year>2016</year><volume>65</volume><issue>9</issue><fpage>1439</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2015-311304</pub-id><pub-id pub-id-type="other">2-s2.0-84960936627</pub-id><pub-id pub-id-type="pmid">26935876</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T.</given-names></name><name><surname>Takahashi</surname><given-names>S.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Changes in the first line <italic>Helicobacter pylori</italic> eradication rates using the triple therapy&#x02014;a multicenter study in the Tokyo metropolitan area (Tokyo <italic>Helicobacter pylori</italic> study group)</article-title><source><italic>Journal of Gastroenterology and Hepatology</italic></source><year>2014</year><volume>29</volume><issue>supplement 4</issue><fpage>29</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/jgh.12796</pub-id><pub-id pub-id-type="other">2-s2.0-84919461894</pub-id><pub-id pub-id-type="pmid">25521730</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishizawa</surname><given-names>T.</given-names></name><name><surname>Maekawa</surname><given-names>T.</given-names></name><name><surname>Watanabe</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Clarithromycin versus metronidazole as first-line helicobacter pylori eradication</article-title><source><italic>Journal of Clinical Gastroenterology</italic></source><year>2015</year><volume>49</volume><issue>6</issue><fpage>468</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1097/MCG.0000000000000165</pub-id><pub-id pub-id-type="other">2-s2.0-84932193569</pub-id><pub-id pub-id-type="pmid">24921211</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>T.</given-names></name><name><surname>Shirai</surname><given-names>N.</given-names></name><name><surname>Sugimoto</surname><given-names>M.</given-names></name><name><surname>Nakamura</surname><given-names>A.</given-names></name><name><surname>Hishida</surname><given-names>A.</given-names></name><name><surname>Ishizaki</surname><given-names>T.</given-names></name></person-group><article-title>Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies</article-title><source><italic>Drug Metabolism and Pharmacokinetics</italic></source><year>2005</year><volume>20</volume><issue>3</issue><fpage>153</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.2133/dmpk.20.153</pub-id><pub-id pub-id-type="other">2-s2.0-25644459349</pub-id><pub-id pub-id-type="pmid">15988117</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>S.</given-names></name><name><surname>Gotoda</surname><given-names>T.</given-names></name><name><surname>Kusano</surname><given-names>C.</given-names></name><name><surname>Iwatsuka</surname><given-names>K.</given-names></name><name><surname>Moriyama</surname><given-names>M.</given-names></name></person-group><article-title>The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy</article-title><source><italic>American Journal of Gastroenterology</italic></source><year>2016</year><volume>111</volume><issue>7</issue><fpage>949</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1038/ajg.2016.182</pub-id><pub-id pub-id-type="other">2-s2.0-84976548292</pub-id><pub-id pub-id-type="pmid">27185079</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flowchart of this study. The details were described in Methods section. EGD, esophagogastroduodenoscopy; UBT, urea breath test; VPZ, vonoprazan; AMX, amoxicillin; CLR, clarithromycin; PPI, proton pump inhibitor; RPZ, rabeprazole; LPZ, lansoprazole.</p></caption><graphic xlink:href="CJGH2017-4385161.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Comparison of eradication rates between vonoprazan- (VPZ-) based regimen and proton pump inhibitor- (PPI-) based regimen. Intention-to-treat (a) and per-protocol (b) analyses. Statistical analysis was performed by <italic>&#x003c7;</italic><sup>2</sup> test. VPZ group, treatment with vonoprazan, amoxicillin, and clarithromycin; PPI group, treatment with rabeprazole or lansoprazole, amoxicillin, and clarithromycin.</p></caption><graphic xlink:href="CJGH2017-4385161.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Comparison of eradication rates between vonoprazan- (VPZ-) based regimen and rabeprazole- (RPZ-) based regimen. Intention-to-treat (a) and per-protocol (b) analyses. Statistical analysis was performed by <italic>&#x003c7;</italic><sup>2</sup> test. VPZ group, treatment with vonoprazan, amoxicillin, and clarithromycin; RPZ group, treatment with rabeprazole, amoxicillin, and clarithromycin.</p></caption><graphic xlink:href="CJGH2017-4385161.003"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">VPZ group (<italic>n</italic> = 72)</th><th align="center" rowspan="1" colspan="1">PPI group (<italic>n</italic> = 69)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value<break/>VPZ versus PPI</th><th align="center" rowspan="1" colspan="1">RPZ group (<italic>n</italic> = 59)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value<break/>VPZ versus RPZ</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (yrs)</td><td align="center" rowspan="1" colspan="1">58 (32&#x02013;80)</td><td align="center" rowspan="1" colspan="1">60 (36&#x02013;77)</td><td align="center" rowspan="1" colspan="1">0.7196</td><td align="center" rowspan="1" colspan="1">61 (36&#x02013;77)</td><td align="center" rowspan="1" colspan="1">0.9299</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">41/72 (57%)</td><td align="center" rowspan="1" colspan="1">40/69 (58%)</td><td align="center" rowspan="1" colspan="1">0.9019</td><td align="center" rowspan="1" colspan="1">35/59 (59%)</td><td align="center" rowspan="1" colspan="1">0.7838</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">22.4 (17.9&#x02013;30.7)</td><td align="center" rowspan="1" colspan="1">22.6 (16.1&#x02013;37.8)</td><td align="center" rowspan="1" colspan="1">0.4780</td><td align="center" rowspan="1" colspan="1">22.7 (16.1&#x02013;37.8)</td><td align="center" rowspan="1" colspan="1">0.3382</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">17/70 (24%)</td><td align="center" rowspan="1" colspan="1">19/67 (28%)</td><td align="center" rowspan="1" colspan="1">0.5883</td><td align="center" rowspan="1" colspan="1">15/57 (26%)</td><td align="center" rowspan="1" colspan="1">0.7932</td></tr><tr><td align="left" rowspan="1" colspan="1">Drinking</td><td align="center" rowspan="1" colspan="1">22/72 (31%)</td><td align="center" rowspan="1" colspan="1">22/67 (33%)</td><td align="center" rowspan="1" colspan="1">0.7727</td><td align="center" rowspan="1" colspan="1">18/57 (32%)</td><td align="center" rowspan="1" colspan="1">0.9007</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidities</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Gastric ulcer</td><td align="center" rowspan="1" colspan="1">1/72 (1.4%)</td><td align="center" rowspan="1" colspan="1">1/69 (1.4%)</td><td align="center" rowspan="1" colspan="1">1.0000</td><td align="center" rowspan="1" colspan="1">1/59 (1.7%)</td><td align="center" rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Duodenal ulcer</td><td align="center" rowspan="1" colspan="1">2/72 (2.8%)</td><td align="center" rowspan="1" colspan="1">2/69 (2.9%)</td><td align="center" rowspan="1" colspan="1">1.0000</td><td align="center" rowspan="1" colspan="1">2/59 (3.4%)</td><td align="center" rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Diabetes</td><td align="center" rowspan="1" colspan="1">8/72 (11.1%)</td><td align="center" rowspan="1" colspan="1">2/69 (2.9%)</td><td align="center" rowspan="1" colspan="1">0.0976</td><td align="center" rowspan="1" colspan="1">2/59 (3.4%)</td><td align="center" rowspan="1" colspan="1">0.1838</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Hypertension</td><td align="center" rowspan="1" colspan="1">14/72 (19.4%)</td><td align="center" rowspan="1" colspan="1">17/69 (24.6%)</td><td align="center" rowspan="1" colspan="1">0.4567</td><td align="center" rowspan="1" colspan="1">16/59 (27.1%)</td><td align="center" rowspan="1" colspan="1">0.2983</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02002;Hyperlipidemia</td><td align="center" rowspan="1" colspan="1">8/72 (11.1%)</td><td align="center" rowspan="1" colspan="1">14/69 (20.3%)</td><td align="center" rowspan="1" colspan="1">0.1333</td><td align="center" rowspan="1" colspan="1">14/59 (23.7%)</td><td align="center" rowspan="1" colspan="1">0.0546</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (IU/L)</td><td align="center" rowspan="1" colspan="1">20 (12&#x02013;37)<sup>a</sup></td><td align="center" rowspan="1" colspan="1">21 (12&#x02013;39)<sup>b</sup></td><td align="center" rowspan="1" colspan="1">0.7424</td><td align="center" rowspan="1" colspan="1">21 (12&#x02013;39)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">0.3131</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (IU/L)</td><td align="center" rowspan="1" colspan="1">17 (7&#x02013;36)<sup>a</sup></td><td align="center" rowspan="1" colspan="1">17 (8&#x02013;68)<sup>b</sup></td><td align="center" rowspan="1" colspan="1">0.4114</td><td align="center" rowspan="1" colspan="1">17 (9&#x02013;68)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">0.1291</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="center" rowspan="1" colspan="1">0.78 (0.52&#x02013;1.27)<sup>a</sup></td><td align="center" rowspan="1" colspan="1">0.78 (0.47&#x02013;1.21)<sup>b</sup></td><td align="center" rowspan="1" colspan="1">0.6356</td><td align="center" rowspan="1" colspan="1">0.78 (0.47&#x02013;1.21)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">0.3345</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin A1c (%)</td><td align="center" rowspan="1" colspan="1">5.6 (5.0&#x02013;7.4)<sup>d</sup></td><td align="center" rowspan="1" colspan="1">5.6 (3.5&#x02013;7.9)<sup>e</sup></td><td align="center" rowspan="1" colspan="1">0.1300</td><td align="center" rowspan="1" colspan="1">5.6 (3.5&#x02013;7.9)<sup>f</sup></td><td align="center" rowspan="1" colspan="1">0.3101</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as median (range) or number (percentage). Statistical analyses were conducted with the Mann&#x02013;Whitney <italic>U</italic> test and chi-square test or Fisher's exact test. VPZ group, treatment with vonoprazan, amoxicillin, and clarithromycin; PPI group, treatment with rabeprazole or lansoprazole, amoxicillin, and clarithromycin; RPZ group, treatment with rabeprazole, amoxicillin, and clarithromycin; AST, aspartate aminotransferase; ALT, alanine aminotransferase. <sup>a</sup><italic>n</italic> = 71, <sup>b</sup><italic>n</italic> = 67, <sup>c</sup><italic>n</italic> = 57, <sup>d</sup><italic>n</italic> = 64, <sup>e</sup><italic>n</italic> = 63, and <sup>f</sup><italic>n</italic> = 54.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Incidence of adverse events.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">&#x02009;</th><th align="center" rowspan="1" colspan="1">VPZ group (<italic>n</italic> = 72)</th><th align="center" rowspan="1" colspan="1">PPI group (<italic>n</italic> = 69)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value VPZ versus PPI</th><th align="center" rowspan="1" colspan="1">RPZ group (<italic>n</italic> = 59)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value VPZ versus RPZ</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Overall</td><td align="center" rowspan="1" colspan="1">19 (26.3%)</td><td align="center" rowspan="1" colspan="1">26 (37.7%)</td><td align="center" rowspan="1" colspan="1">0.1505</td><td align="center" rowspan="1" colspan="1">20 (33.9%)</td><td align="center" rowspan="1" colspan="1">0.3497</td></tr><tr><td align="left" rowspan="1" colspan="1">Loose stool</td><td align="center" rowspan="1" colspan="1">12 (16.6%)</td><td align="center" rowspan="1" colspan="1">12 (17.4%)</td><td align="center" rowspan="1" colspan="1">0.9089</td><td align="center" rowspan="1" colspan="1">9 (15.3%)</td><td align="center" rowspan="1" colspan="1">0.8265</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhea</td><td align="center" rowspan="1" colspan="1">6 (8.3%)</td><td align="center" rowspan="1" colspan="1">10 (14.5%)</td><td align="center" rowspan="1" colspan="1">0.2490</td><td align="center" rowspan="1" colspan="1">8 (13.6%)</td><td align="center" rowspan="1" colspan="1">0.3354</td></tr><tr><td align="left" rowspan="1" colspan="1">Dysgeusia</td><td align="center" rowspan="1" colspan="1">3 (4.1%)</td><td align="center" rowspan="1" colspan="1">6 (8.7%)</td><td align="center" rowspan="1" colspan="1">0.3192</td><td align="center" rowspan="1" colspan="1">5 (8.5%)</td><td align="center" rowspan="1" colspan="1">0.4664</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin eruption</td><td align="center" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" rowspan="1" colspan="1">3 (4.3%)</td><td align="center" rowspan="1" colspan="1">0.3591</td><td align="center" rowspan="1" colspan="1">2 (3.4%)</td><td align="center" rowspan="1" colspan="1">0.5881</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdominal bloating</td><td align="center" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" rowspan="1" colspan="1">2 (2.9%)</td><td align="center" rowspan="1" colspan="1">0.6143</td><td align="center" rowspan="1" colspan="1">1 (1.7%)</td><td align="center" rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">Epigastralgia</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">2 (2.9%)</td><td align="center" rowspan="1" colspan="1">0.2377</td><td align="center" rowspan="1" colspan="1">2 (3.4%)</td><td align="center" rowspan="1" colspan="1">0.4504</td></tr><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td align="center" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" rowspan="1" colspan="1">1.0000</td><td align="center" rowspan="1" colspan="1">1 (1.7%)</td><td align="center" rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="center" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" rowspan="1" colspan="1">1 (1.4%)</td><td align="center" rowspan="1" colspan="1">1.0000</td><td align="center" rowspan="1" colspan="1">1 (1.7%)</td><td align="center" rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">Others</td><td align="center" rowspan="1" colspan="1">2 (2.8%)</td><td align="center" rowspan="1" colspan="1">4 (5.8%)</td><td align="center" rowspan="1" colspan="1">0.4348</td><td align="center" rowspan="1" colspan="1">3 (5.1%)</td><td align="center" rowspan="1" colspan="1">0.6571</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as number (percentage). Statistical analyses were conducted with the chi-square test or Fisher's exact test. VPZ group, treatment with vonoprazan, amoxicillin, and clarithromycin; PPI group, treatment with rabeprazole or lansoprazole, amoxicillin, and clarithromycin; RPZ group, treatment with rabeprazole, amoxicillin, and clarithromycin.</p></fn></table-wrap-foot></table-wrap></floats-group></article>